Charles Vernon Eddy was born in Winchester on September 13, 1877. He was the son of Florence Alberta “Bertie” Snapp Eddy and James Clarkson Eddy, a millwright who died of tuberculosis in 1888. He and his brother established a printing business in 1892 while students at the Shenandoah Valley Academy, from which Eddy graduated in 1896. He married Katharine Graham Kurtz on March 22, 1905. They had three sons, one of whom died in infancy.
The Eddy Press, as the business was later named, expanded to become one of the state’s largest printing operations and included an office in New York, but financial difficulties led to a declaration of bankruptcy in 1904. The company was later sold. Eddy remained with the Eddy Press until about 1907, when he moved with his family to Philadelphia and became an assistant manager of a printing house there.
Norwich leads the Vermont Initiative for Biological and Environmental Surveillance with wastewater testing
vermontbiz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vermontbiz.com Daily Mail and Mail on Sunday newspapers.
Norwich University leads the Vermont Initiative for Biological and Environmental Surveillance with wastewater testing
norwich.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from norwich.edu Daily Mail and Mail on Sunday newspapers.
UK-based CRO Charnwood Molecular reveals plans for ‘significant’ expansion in 2021
29th April 2021
Charnwood Molecular recently announced a partnership with private equity fund Synoya to further its expansion plans.
This deal, according to the CRO, provided additional capital to support the company’s future development and growth, including hiring additional senior leadership team members.
The expansion plans include Charnwood Molecular becoming the sole occupier of a ‘state-of-the-art’ laboratory facility at Charnwood Campus, based in Loughborough.
This campus was recently designated a ‘Life Sciences Opportunity Zone’, Charnwood Molecular said in a statement, allowing for greater collaboration and accelerated business growth within the med-tech and biopharma industries.